BioMarin Pharmaceutical (NASDAQ:BMRN) is one of the best large cap stocks under $100 with huge upside potential. On January 20, Canaccord Genuity analyst Whitney Ijem revised her Hold rating on BioMarin Pharmaceutical (NASDAQ:BMRN) to Buy. She also raised her price target estimate from$84 to $98, offering an upside of almost 75% from the prevailing level. Illumina (ILMN) Jumps 24.8% on Earnings Beat RAJ CREATIONZS / shutterstock.com Ijem’s upward revisions are based on the company’s encouraging fundam ...